News
BNTC
--
0.00%
--
Pfizer Internal Target Is For 3B Doses Of COVID-19 Vaccine In 2021
-Reuters
Reuters · 1d ago
Mid-Afternoon Market Update: Dow Drops 90 Points; Fed Leaves Rates Unchanged
Toward the end of trading Wednesday, the Dow traded down 0.26% to 33,894.93 while the NASDAQ fell 0.01% to 14,090.09. However, the S&P gained 0.13% to 4,192.05.
Benzinga · 04/28 18:37
PINS, CLOV, ENPH and PBI among midday movers
Gainers: Brooklyn ImmunoTherapeutics (BTX) +44%.Uxin (UXIN) +25%.Ashford Hospitality Trust (AHT) +24%.Boxlight (BOXL) +21%.ADMA Biologics (ADMA) +18%.Clover Health Investments (CLOV) +16%.Unitil (UTL) +15%.Pitney Bowes (PBI) +15%.ClearSign Technologies (CL...
Seekingalpha · 04/28 16:41
Mid-Day Market Update: Crude Oil Rises 2%; Protalix BioTherapeutics Shares Plunge
Midway through trading Wednesday, the Dow traded down 0.33% to 33,874.02 while the NASDAQ fell 0.07% to 14,079.66. The S&P also rose, gaining 0.15% to 4,193.17.
Benzinga · 04/28 16:20
41 Stocks Moving In Wednesday's Mid-Day Session
Gainers Aurora Mobile Limited (NASDAQ: JG) shares climbed 21.3% to $4.27 after Oppenheimer initiated coverage on the stock with an Outperform rating and a price target of $6 per share.
Benzinga · 04/28 16:06
Why Is It Moving? Looking Into Why Benitec Biopharma's Stock is Trading Lower Today
The Price And Volume Action In Benitec Biopharma's Stock Today Benitec Biopharma (NASDAQ:BNTC) is currently down 24.48% to a price of $4.12. The stock's volume is currently 1.10 million, which is roughly 20.92% of its recent 30-day volume average of 5.25 m...
Benzinga · 04/28 15:23
ADMA Biologics, Brooklyn ImmunoTherapeutics leads healthcare gainers; Protalix BioTherapeutics, Benitec Biopharma among major losers
Gainers: ADMA Biologics (ADMA) +25%, Brooklyn ImmunoTherapeutics (BTX) +23%, Clover Health Investments (CLOV) +15%, Neptune Wellness Solutions (NEPT) +12%, Akouos (AKUS) +11%.Losers: Protalix BioTherapeutics (PLX) -40%, Benitec Biopharma (BNTC) -25%, BioVi...
Seekingalpha · 04/28 15:01
Mid-Morning Market Update: Markets Mixed; Alphabet Tops Q1 Expectations
Following the market opening Wednesday, the Dow traded down 0.43% to 33,839.68 while the NASDAQ rose 0.10% to 14,104.41. The S&P also rose, gaining 0.19% to 4,194.68.
Benzinga · 04/28 14:12
Spotify Technology, Pinterest among premarket losers' pack
Protalix BioTherapeutics (PLX) -43% on FDA rejection of experimental therapy for Fabry disease.Benitec Biopharma (BNTC) -22% after secures $13M capital via equity offering.Urban Tea (MYT) -13% on 1H earnings releasePinterest (PINS) -12% on Q1 earnings rele...
Seekingalpha · 04/28 12:26
The Daily Biotech Pulse: FDA Rejection For Protalix, Amgen Q1 Trail Estimates, Pfizer Goes Shopping
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 27)
Benzinga · 04/28 11:26
25 Stocks Moving in Wednesday's Pre-Market Session
Gainers RiceBran Technologies (NASDAQ: RIBT) rose 16.1% to $1.37 in pre-market trading after jumping around 27% on Tuesday. The company is scheduled to report Q1 earnings today.
Benzinga · 04/28 11:01
Benitec Bio secures $13M capital via equity offering
Benitec Biopharma's (BNTC) underwriter has agreed to increase the size of the previous offering and purchase on a firm commitment basis ~3M shares of common stock at $4.25/share.Expected gross proceeds
Seekingalpha · 04/28 04:01
BRIEF-Benitec Biopharma Increases Previously Announced Bought Deal Offering Of Common Stock To $12.9 Million
reuters.com · 04/28 01:59
Benitec Biopharma enters $7.5M bought deal offering
Benitec Biopharma (BNTC) has entered into an underwriting agreement with H.C. Wainwright of 1.76M shares at a price of $4.25/share, with expected gross proceeds of $7.5M.Company has also granted the underwriter
Seekingalpha · 04/27 20:49
Benitec Biopharma Announces $7.5 Million Bought Deal Offering of Common Stock
PR Newswire · 04/27 20:44
Chembio Diagnostics, Nano-X Imaging leads healthcare gainers; Molecular Templates, ACADIA Pharmaceuticals among major losers
Gainers: Chembio Diagnostics CEMI +60%, Nano-X Imaging NNOX +25%, NanoVibronix (NAOV) +16%, Vivos Therapeutics (VVOS) +15%, Greenwich LifeSciences (GLSI) +14%.Losers: Molecular Templates (MTEM) -26%, ACADIA Pharmaceuticals ACAD -17%, Benitec Biopharma (BNT...
Seekingalpha · 04/05 15:00
BRIEF-Steven M. Oliveira Reports A Passive Stake Of 8.20% In Benitec Biopharma As Of April 1, 2021
reuters.com · 04/05 10:16
FCEL, QS, NNDM and CHPT among premarket gainers
Sonoma Pharmaceuticals SNOA +28% on agreement with EMC pharma.Future FinTech Group FTFT +24% on acquiring bitcoin mining farm.AeroCentury (ACY) +22%.Jaguar Health JAGX +19% on FY results.P&F Industries (PFIN) +21%.AgEagle Aerial Systems UAVS +19% on FY res...
Seekingalpha · 04/01 12:20
QuantumScape, RLX Technology among premarket losers' pack
WISeKey International Holding (WKEY) -27%.Evofem Biosciences (EVFM) -25% after secures $30M capital via equity raise.Dolphin Entertainment (DLPN) -20%.Takung Art Co (TKAT) -14%.Riot Blockchain (RIOT) -13%.Hall of Fame Resort & Entertainment (HOFV) -13%.Sen...
Seekingalpha · 03/25 12:35
FNKO, IQ, CIDM and PLL among midday movers
Gainers: Aptose Biosciences (APTO) +80%.Color Star Technology (CSCW) +69%.Hall of Fame Resort & Entertainment (HOFV) +51%.Dolphin Entertainment (DLPN) +42%.Phoenix New Media (FENG) +32%.Funko (FNKO) +27%.Vinco Ventures (BBIG) +26%.Cinedigm (CIDM) +23%.Euro...
Seekingalpha · 03/24 16:40
Webull provides a variety of real-time BNTC stock news. You can receive the latest news about Benitec Biopharma through multiple platforms. This information may help you make smarter investment decisions.
About BNTC
Benitec Biopharma Inc. formerly Benitec Biopharma Limited, incorporated on April 7, 1995, a is a clinical-stage biotechnology company. The Company focused on the development of genetic medicines. The Company is developing a therapeutic technology platform that combines Ribonucleic acid (RNA) interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. The Company is using this technology, called Deoxyribonucleic acid (DNA)-directed RNA interference, or ddRNAi, to develop product candidates in chronic and life-threatening human disease areas including orphan disease and infectious disease. Benitec endeavors to develop and commercialize BB-301 for the treatment of Oculopharyngeal Muscular Dystrophy, or OPMD. The Company’s pipeline includes Oculopharyngeal Muscular Dystrophy (OPMD) Hepatitis B BB-103.